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Mycobacterium celatum is a nontuberculous mycobacterium shown to cause symptoms similar to pulmonary M. tuberculosis.
Certain strains have been shown to cross-react with the probes used to detectM. tuberculosis, making this a diagnostic challenge.
We present a 56-year-old gentleman who developed signs and symptoms of lung infection with computed tomography scan of the
chest showing right lung apex cavitation. Serial sputum samples were positive for acid-fast bacilli and nucleic acid amplification
testing identified M. tuberculosis ribosomal RNA, resulting in treatment initiation. Further testing with high performance liquid
chromatography showed a pattern consistent with M. celatum. This case illustrates the potential for M. celatum to mimic M.
tuberculosis in both its clinical history and laboratory testing due to the identical oligonucleotide sequence contained in both.
An increasing number of case reports suggest that early reliable differentiation could reduce unnecessary treatment and public
health intervention associated with misdiagnosed tuberculosis.
1. Introduction
Mycobacterium celatumwas first described in humans in 1993
[1]. It is a member of the slow-growing nonchromogens, non-
tuberculous mycobacterium, which exists along with 150
other currently identified rapid-growing and slow-growing
species [2]. It has been shown to cause fatal disease in both
immunocompetent and immunocompromised patients.
M. celatum andM. tuberculosis can present with a similar
clinical picture: cough, weight loss, lung infiltrates, or cavitary
lesions; thus, differentiation between these 2 organisms can
be difficult. Although culture remains the gold standard
for diagnosis, identification using nucleic acid amplification
testing (NAAT) provides a much faster answer and saves a
considerable amount of time. It is highly sensitive [3] and
allows for faster initiation of therapy weeks before definitive
culture results return. A challenge exists with diagnosing this
type of mycobacterium, as it has been found to cross-react
with the current probes used to diagnoseM. tuberculosis.
Here we describe a case of a middle-aged immunocom-
promised patient who was misdiagnosed and treated for
tuberculosis but ultimately was found to haveM. celatum.
2. Case Presentation
Our patient is a 56-year-old man with medical history signif-
icant for common variable immune deficiency on biweekly
intravenous immunoglobulin therapy who presented initially
to Henry Ford Hospital for evaluation for fecal transplanta-
tion for Clostridium difficile diarrhea refractory to medical
management.The patient underwent his first fecal transplant
with transient improvement, but his diarrhea recurred and he
subsequently failed 3 further fecal transplants. He was finally
initiated on long-term oral vancomycin with symptom reso-
lution.
His hospital coursewas complicated by increasing oxygen
requirements from a baseline of 2 L/min at home to 6 L/min.
Lung auscultation revealed diffuse rhonchi and decreased
breath sounds on the right side. He was afebrile and had
increasing low to normalwhite blood cell counts in the prior 3
days (2.6–6.0× 109/L). Chest X-ray showed diffuse consolida-
tion throughout the right lung consistent with pneumonia
(Figure 1), and he was started on intravenous antibiotics for
treatment of hospital-acquired pneumonia.
Hindawi Publishing Corporation
Case Reports in Infectious Diseases
Volume 2016, Article ID 1761923, 3 pages
http://dx.doi.org/10.1155/2016/1761923
2 Case Reports in Infectious Diseases
Figure 1: Chest X-ray showing diffuse consolidation throughout the
right lung.
R
Figure 2: Chest computed tomography scan showing cavitary lesion
in the right lung apex.
Three days after initiating therapy, the patient still
remained short of breath and hypoxic. Computed tomogra-
phy scan of the chest was obtained, which showed consolida-
tion within the right lung apex with areas of central lucency
suggesting cavitation (Figure 2).
Serial sputum samples were positive for acid-fast bacilli,
andNAAT (Enhanced AmplifiedMycobacterium tuberculosis
Direct Test, Gen-Probe, San Diego, CA) run by the state
of Michigan, identified M. tuberculosis complex ribosomal
RNA, providing the diagnosis of tuberculosis.Thepatient was
started on isoniazid, ethambutol, pyrazinamide, and rifampin
while awaiting results of cultures.
A second non-NAAT test (AccuProbe, Hologic, Marlbor-
ough, MA) was run and came back negative for tuberculosis.
Two weeks later, high performance liquid chromatography
showed a pattern consistent with M. celatum, and the 4-
drug regimen was changed to ethambutol, azithromycin, and
moxifloxacin. Final cultures confirmed the result.
3. Discussion
M. celatum is a slow-growing, nontuberculous mycobac-
terium that is morphologically similar to Mycobacterium
avium complex [3]. It can be divided into 3 types, 1, 2, and
3, based on their genomic sequencing. Previous reports have
shown cross-reactivity between M. celatum types 1 and 3
and the genetic probe for the M. tuberculosis complex. The
purpose of this correspondence is to add to the literature
supporting this phenomenon and to report it in a CVID
patient and summarize the current evidence.
M. celatum has been classically described in patients with
acquired immunodeficiency syndrome [4], with less than a
handful of cases described in immunocompetent patients [5].
Even in AIDS patients, it was only isolated on rare occasions.
In a retrospective analysis by Butler et al. [6], the rate of isola-
tion ofM. celatum was determined by examination of 13,530
laboratory isolates over a period of 5 years. M. celatum was
found in 24 isolates from 17 different patients.The rate of iso-
lation ofM. celatum types 1 and 2 was only 0.1%, and the rate
of isolation ofM. celatum type 1, which is the type responsible
for discrepant reactions with genetic probes, is only 0.05%. A
subsequent review including type 3 has not been performed.
It is also noted that patients with CVID have not been
shown to have increased risk of infection from Mycobac-
terium species [7].
In our case, M. tuberculosis was diagnosed based on
the direct detection of ribosomal RNA by NAAT. Currently,
2 NAATs, enhanced amplified Mycobacterium tuberculosis
Direct Test and Amplicor Mycobacterium tuberculosis Test
(Roche Diagnostics, Basel, Switzerland), have been approved
by the US Food and Drug Administration for testing respi-
ratory specimens that are smear-positive for acid-fast bacilli
[8]. These commercially available genetic probes are short
oligonucleotide sequences and the sequence that is within the
target 16S rDNA region for these probes contains a limited,
homologous region that differs by only a single nucleotide in
both M. tuberculosis and M. celatum type 1 [9]. It has also
been shown that these probes are temperature-dependent
and the rate of false-positive identification increases outside
the temperature range of 60-61∘C.
A meta-analysis from 2006 [3] showed pooled NAAT
sensitivities and specificities of 96% and 85%, respectively, on
smear-positive samples and 66% and 98%, respectively, for
smear-negative samples, making it a strong test to exclude TB
on smear positive samples and confirmTB on smear negative
samples.
Based on these numbers and given the rarity of M.
celatum, treatment forM. tuberculosis and airborne isolation
should still be initiated based on NAAT result. However,
correct identification, either by final culture results or by high
performance liquid chromatography, remains of importance
as M. celatum is known to have low in vitro susceptibility to
many antituberculous medications [10].
Different regimens with combinations of antimycobacte-
rial agents have been proposed, mainly ethambutol and clar-
ithromycin. A third drug is usually added, such as moxi-
floxacin in our case or rifabutin [11] and isoniazid [12, 13]. Our
species was pan-susceptible to all agents including ciprofloxa-
cin, linezolid, rifampin, and trimethoprim/sulfa as well as to
the agents that were ultimately used for treatment in the case
above.
Newer probes including the INNO-LiPA Mycobacteria
(Innogenetics, Ghent, Belgium) and Geno-Type Mycobac-
terium (Hain Lifescience, Nehren, Germany) have included
probes specific for 16 and 13 different mycobacterium species,
respectively, including M. celatum [14]. However, they also
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were found to have issues with misidentification of certain
species, namely,M. smegmatis identified asM. fortuitum and
M. thermoresistibile identified asM. celatum. While any test’s
sensitivity and specificity depend on the population preva-
lence, with multiple case reports regardingM. celatum infec-
tion, the last in 2013 also at Henry Ford Hospital in Detroit
[15], we argue that the use of probes specific for M. celatum
could help prevent misdiagnosis, inappropriate treatment,
and the emotional hardship incurred in contact tracing of
familymembers as well as healthcare workers for tuberculosis
testing (these writers included).
Fortunately, M. celatum is only rarely encountered, and
the commercial probes currently available remain highly
sensitive and specific. Their continued use as a means of
rapidly identifyingM. tuberculosis complex remains clinically
relevant at this time, although it is our hope thatmore specific
probes will become a more cost-effective option in the future
to prevent misdiagnosis.
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